Abstract 625P
Background
Tumor markers have been used for cancer screening and monitoring, yet their potential connection with air pollution remains largely unexplored. We aimed to examine the potential association between various air pollutants – including carbon monoxide (CO), nitrogen dioxide (NO2), sulfur dioxide (SO2), PM2.5, and PM10 – and the levels of tumor markers (AFP, CEA, CA19-9, CA125, and PSA) within the general population.
Methods
Our study included 10,067 men and 9,598 women in its final analysis. We assessed each individual's annual average exposure to five distinct air pollutants: PM2.5, PM10, NO2, SO2, and CO. Additionally, we measured serum concentrations of AFP, CEA, CA19-9, CA125, and PSA.
Results
After adjusting for potential confounding factors, we discovered noteworthy associations. Both men and women demonstrated a negative correlation between annual average exposure to SO2 and PM10 and AFP concentration (all P < 0.05). In men, after multivariate adjustment, exposure to CO, NO2, SO2, and PM10 showed negative correlations with CEA concentration (all P < 0.05). Furthermore, in men, exposure to CO, NO2, and PM10 exhibited positive associations with PSA concentration after multivariate adjustment (all P < 0.05). Among women, a similar multivariate analysis indicated that SO2 exposure was negatively correlated with CEA concentration (all P < 0.05).
Conclusions
Our study presents the first evidence of a potential link between air pollution exposure and tumor markers within the general population. To establish the validity of these associations, further investigations employing prospective analyses are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract